Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment

被引：0

作者：

Sands, Bruce E. ^{[1
]}

Kobayashi, Taku ^{[2
]}

Wu, Jianmin ^{[3
]}

Wang, Isabella Yali ^{[3
]}

Zhu, Baojin ^{[3
]}

Redondo, Isabel ^{[4
]}

Peyrin-Biroulet, Laurent ^{[5
,6
]}

Walsh, Alissa ^{[7
]}

Magro, Fernando ^{[8
,9
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY USA

[2] Kitasato Univ, Kitasato Inst Hosp, Minato City, Tokyo, Japan

[3] Eli Lilly & Co, Indianapolis, IN USA

[4] Eli Lilly & Co, Lisbon, Portugal

[5] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM,NGERE, Vandoeuvre Les Nancy, France

[6] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[7] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England

[8] Univ Porto, Porto, Portugal

[9] Ctr Hosp, Porto, Portugal

来源：

关键词：

D O I：

10.14309/01.ajg.0001035164.22459.94

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1449

引用

页码：S1042 / S1043

页数：2